Prabhudas Lilladher: Pharma Day Conference Takeaways - Optimistic FY22 Guidance, Outlook
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We hosted few pharmaceutical companies on December 03-04, 2020 on a digital platform. Key takeaways for the sector were -
1. India branded formulations segment is back on track with medical representatives back on field with full force, cost savings to diminish in H2 FY21E.
2. Companies increased their inventory days for active pharmaceutical ingredient post Covid-19 due to unstable environment.
3. Travel restriction stay in place for U.S. Food and Drug Administration inspectors, which could delay resolution of plants and new approvals while virtual audit still not a reality.
4. New Abbreviated New Drug Application filing rate to be lower in FY21E due to Covid-19.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.